What are the targets of brigatinib?

Brigatinib (Brigatinib) is a targeted drug that targets ALK (anaplastic lymphoma kinase) gene mutations and is used to treat ALK gene mutation-positive non-small cell lung cancer (NSCLC). Its targets mainly include the following aspects:

1. ALKkinase: The main target of brigatinib is ALKkinase. ALKGene mutations lead to abnormal activation of ALKkinase. This activation promotes the growth and division of cancer cells. Brigatinib binds to ALK kinase and inhibits its phosphorylation activity, thereby blocking the signaling pathways for cancer cell proliferation and survival. The drug can effectively interfere with the function of ALK kinase and inhibit its tumor-promoting effect.

2. ALKMutants: In addition to inhibiting common ALKkinase activity, Brigatinib (Brigatinib) also has a targeting effect on a variety of ALKmutants. For example, Brigatinib also shows a certain inhibitory effect on secondary mutations of the ALK gene (such as G1202R). Because these mutants can render cancer cells resistant to other ALK inhibitors, the role of brigatinib in these resistant mutants is particularly important.

3. ROS1kinase: Although the main target of brigatinib is ALKkinase, it also has a certain inhibitory effect on ROS1kinase. ROS1 gene mutations are similar to ALK mutations and can cause abnormal growth of cancer cells. Brigatinib may provide additional treatment options by inhibiting ROS1kinase activity, particularly in the presence of ROS1In patients with genetic mutations.

Brigatinib mainly targetsALKkinase and its mutants, and also has a certain inhibitory effect onROS1kinase. Its strong central nervous system penetration gives it significant advantages in the treatment of brain metastases. Compared with other ALK inhibitors, brigatinib offers more targets and treatment options, especially when dealing with drug-resistant mutations and complex conditions.